Retrospective Evaluation of the Efficacy of Combined Antiviral Therapy Versus Monotherapy in High-Risk Hospitalized COVID-19 Patients
Abstract
The COVID-19 pandemic has led to a variety of clinical symptoms, ranging from mild respiratory problems to severe pneumonia and multi-organ failure. Remdesivir and favipiravir are approved to treat COVID-19 and are used as single agents in the Ministry of Health (MOH) protocol. However, there is limited research available on the effectiveness of their combined use. The aim of this cross-sectional study is to evaluate the efficacy and safety of remdesivir and favipiravir in reducing disease severity, hospitalization duration, and mortality rates among high-risk patients who have been hospitalized with COVID-19. A retrospective, cross-sectional study was conducted in adult patients who were treated with the MOH treatment protocol. The study period was from January 2021 to January 2022, and it included 47 patients treated with favipiravir or a combination of remdesivir and favipiravir. The study included patients with high-risk characteristics and excluded pediatric and pregnant patients. In a study of 47 hospitalized COVID-19 patients, all admitted cases presented with at least one COVID-19 symptom. The frequency of symptoms such as fever, cough, chest pain, shortness of breath, and fatigue was noted to be, respectively. The median duration of antiviral therapy was seven days (interquartile range (IQR): five to eight days), and one-third of study participants developed side effects due to antiviral administration. The proportions of renal and hepatic side effects were found to…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 47 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.